Agmatine Stats & Data

Agmatine is an endogenous amine formed by L‑arginine decarboxylation; in the CNS it binds imidazoline and alpha‑2 adrenergic sites, and it blocks NMDA receptor channels at high micromolar concentrations; it also down‑regulates iNOS expression, with anti‑inflammatory/neuroprotective signals in preclinical work. In animals, agmatine potentiates morphine analgesia and can reduce opioid tolerance; in people, users report potentiation with both RX opioids and kratom—raising sedation/overdose risk if baseline doses are not lowered. Small human data exist: an open‑label case series (n=11 completers) used 2.67 g/day agmatine sulfate for 2 months and reported meaningful reductions in neuropathic pain without major adverse events, but the study had conflicts of interest and no control arm; findings should be considered preliminary. Blood pressure: due to central imidazoline/I1 and alpha‑2 actions, agmatine can lower BP; additive effects occur with clonidine‑like drugs; stand up slowly and avoid rushed dose escalations. Glucose: secondary pharmacology summaries and some preclinical data suggest mild hypoglycemic effects; individuals on insulin or sulfonylureas should monitor for low glucose when starting. Route risks: intranasal use is discouraged—agmatine sulfate is acidic and can cause nasal irritation; scattered user reports describe unpleasant dissociation and anxiety with this route. Psychiatric variability: while some users report anxiolysis or mood lift, others experience flattening, brain fog, anxiety spikes, or depersonalization—if these occur, discontinue. Tolerance/poop‑out: many users report tachyphylaxis with daily use; if using for mood or pain, consider intermittent schedules to assess continued benefit. Pregnancy, breastfeeding, significant renal or hepatic disease: data are insufficient—avoid or use only with medical supervision. As a supplement, product quality varies; prefer products with recent third‑party testing and avoid proprietary blends with unclear agmatine amounts.